BRAF and melanoma: Pre-treatment of melanoma cells with AM404 + GSK126 combination led also to a significant increase in melanoma cell death in response to PLX4720 at 72 h in two BRAF-mutant and PLX4720-resistant melanoma cell lines (Supplementary Fig. S20c).